Fibromyalgia Care Breakthrough: DEA Green Lights Biotech Partnership Exploring Ketamine Implant Therapy
Silo Pharma’s (NASDAQ: SILO) novel ketamine-loaded implant targeting fibromyalgia and chronic pain conditions, SP-26, is reportedly ad
What’s Going On With Marijuana-Giant Tilray Brands?
Tilray Brands, Inc. (NASDAQ: TLRY) shares are trading higher Thursday, and the stock is up by more than 20% over the past five days.
CBD Of Denver’s Success In Challenging Climate With Increase In Q4 Revenue
CBD of Denver has reported strong fourth-quarter revenues of approximately $1.31m, with $1.13m generated by Luxora and $176,000 by Libra 9. The CBD company attributed its growth to a number of factors, including its partnership with EDEKA and the popularity of its Magic Lappen product, both of which increased sales across Germany. CBD of Denver also highlighted the success of Libra 9's attendance at trade shows, which boosted brand recognition and allowed the company to form several significant partnerships. Meanwhile, Luxora's expansion into the European CBD wholesale market was credited with contributing significantly to the company's growth. Following the German government's expected approval of relevant legislation, Luxora Solutions will expand further into the German market. Germany's decision on legalising marijuana, which was set to be made in December, has been delayed until next year.
Cannabis Co. Vext Announces Debt Conversion, Opens Door To 27 Million Shares For Investors
Vext Science has reached agreements with the holders of the company's existing secured non-convertible debentures to convert the outstanding principal amount of $4.6m, plus interest and a conversion incentive fee, into 27,700,625 common shares of the company. The conversion is subject to regulatory approval and is expected to be completed in due course. Upon completion, all existing security held by the debenture holders will be released and discharged. Sopica Special Opportunities Fund Limited, an insider shareholder of Vext Science, is a debenture holder and is expected to acquire common shares as part of the conversion transaction.
From Snoop Dogg Video Blasting Trump To GOP Admitting Legal Weed Undercuts Drug Cartels: Benzinga’s Most-Read Pot Stories Of 2023
What was the most exciting cannabis news of 2023?
Tesla Investor Ross Gerber Calls On DEA To Reschedule Cannabis: ‘Absurd We’re Still Waiting’
It wasn’t long ago when Ross Gerber, president and CEO of Gerber Kawasaki Wealth and Investment Management and an enthusiastic Tesla Inc (NASDAQ: TSLA)
Marijuana Stock Movers For December 27, 2023
GAINERS: Affinor Growers (OTC:RSSFF) shares closed up 668.00% at $0.06 GrowLife (OTC:PHOT) shares closed up 42.86% at $0.001…
Curaleaf’s Boris Jordan Predicts Major Turnaround For Cannabis In 2024
Boris Jordan of Curaleaf foresees a major rebound for the cannabis industry in 2024, driven by new markets and legislative shifts.
Cannabis 2024: Experts Weigh In, What To Expect From DC And Business Outlook ‘Exciting Point In Time’
With another year behind us with no federal legalization of marijuana and no approval of the SAFE Banking Act, the industry’s biggest problem remains the lack of access to capital. What will happen in 2024? Are we any closer to either of these reforms?
Psyched: Biden Approves Psychedelics Trials, RFK, Australia’s First Legal Dedicated Clinic & More
President Biden Approves Psychedelics Clinical Trials For Active Military Members
President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also contains a mandate to fund clinical trials with psychedelics for active service members.